TMDX stock sentiment todayTransMedics Group, Inc.
Sentiment verdict
Gossip first, financials second — HOT at 85% confidence.
Last updated · cached analysis, refreshes periodically
TMDX
TransMedics Group, Inc.A category-defining medical technology play with a massive logistics moat, currently offering a high-growth entry point after a significant pullback from all-time highs.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for TMDX. Not financial advice.
Price · last 12 months
Gossip
The narrative is currently a tug-of-war between long-term growth bulls who see a 'FedEx for Organs' and short-term bears spooked by a Q3 earnings miss and decelerating sequential growth. Chatter focuses on the massive investment in their own aviation fleet and whether they can maintain 50%+ margins while scaling logistics.
- ·TransMedics Aviation expansion efficiency
- ·Short-seller interest regarding aircraft maintenance costs
- ·Market share dominance in the NRP (Normothermic Regional Perfusion) space
- ·Recent 40% drawdown from summer highs creating 'buy the dip' sentiment
Financial
TransMedics is in a rare hyper-growth phase, recently turning GAAP profitable. While R&D and CAPEX for their fleet are high, their triple-digit revenue growth and expansion of the Organ Care System (OCS) into heart, lung, and liver segments provide a robust fundamental floor.
- ·Revenue growth: 64% YoY (Q3 2024)
- ·Gross Margin: ~56% (impacted by aviation costs)
- ·Cash Position: ~$330M providing sufficient runway
- ·Valuation: Price/Sales ~12x (historically low for this growth profile)
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Insiders bought a net $109K on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·High capital intensity of the aviation logistics model
- ·Dependency on transplant volume trends
- ·Regulatory hurdles for new organ indications
- ·Potential for increased competition in NRP technology
Peer temperature
How direct competitors stack up against TMDX right now.
- NEUTRALISRGIntuitive Surgical
COLDER — significantly lower growth rate (17%) and higher P/E, though boasting much more stable recurring revenue and cash flow.
See full analysis → - COLDEWEdwards Lifesciences
COLDER — facing stagnant top-line growth and recent divestitures, making TMDX's expansion narrative far more attractive to growth investors.
See full analysis → - NEUTRALABTAbbott Laboratories
COLDER — offers safety and dividends but lacks the disruptive, winner-take-all potential of TMDX's specific organ preservation niche.
See full analysis →
- TMDX-20.9%
- ISRG+6.2%
- EW+6.6%
- ABT+7.5%
Analyst price target
Consensus average of 10 analysts · median 100.00
Source: StockAnalysis.com · updated 2026-10-15
AI-generated analysis for informational purposes only. Not financial advice.